PubMed · 14828967
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
G SCHAFER. 1950. [Ovarian function and plasmalogen].. https://pubmed.ncbi.nlm.nih.gov/14828967/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
When nanoparticles are injected into the blood for drug delivery or drug detoxification, detrimental interaction of these particles with blood constituents must be avoided. In previous studies, the adsorption of albumin immunoglobulin G, and fibrinogen from blood plasma to a model hydrophobic polymer like polystyrene was investigated as was decreasing surface hydrophobicity, which quantitatively leads to decreasing amounts of adsorbed proteins on latex particles. However, the uptake of other blood constituents, such as inorganic blood electrolytes, by particles and the dispersion/coagulation characteristics of these particles in the blood stream have not been fully studied. Most importantly, the effect s of these particles on blood coagulation and hemolysis are not well known. In the present study, the poly(lactide-co-glycolide) acid(PLGA) nanoparticles were synthesized by using nanoprecipitation. The uptake of blood electrolytes from simulated blood fluid (SBF) and the stability (dispersion/aggregation) of nanoparticles in SBF was examined by using different loading amounts of PLGA and different contact time between PLGA nanoparticles and SBF. The interaction of particles with the organic components of blood was also studied by using the measurement of red blood cell hemolysis and blood clotting with raw PLGA, surfactant modified PLGA, and PEGylated PLGA.
Gradiflow is new technology allowing purification of important blood proteins from viral contaminated plasma. Protein purification is based on unique scalable tangential-flow preparative electrophoresis, and is distinct from current technology because protein purification and virus removal are performed in the same step. This one-step removal and purification exploits both the size and charge of target proteins. The medically important blood proteins, immunoglobulin G (IgG) and alpha-1-antitrypsin, were chosen to demonstrate the ability of this process to purify proteins from contaminated plasma. Clearance factors achieved by infectivity assays and polymerase chain reaction (PCR) that meet regulatory requirements demonstrated removal of canine parvovirus (CPV). CPV is a model virus for pathogenic nonenveloped viruses, including parvovirus B19, not adequately removed or inactivated by most processes currently in practice. The recovery of proteins from plasma with high purity, recovery, and function, while simultaneously removing viruses, provides blood products with a level of purity compatible with clinical use more quickly and cheaply than available techniques.
Thiol groups were attached to polyethylene terephthalate (PET) to promote the transfer of a known platelet inhibitor, nitric oxide (NO), from nitrosated thiols naturally found in the body to PET, followed by the release of NO from PET to prevent platelet adhesion. In order to immobilize the most thiols on the modified polymer, the processing parameters used to attach the following three thiol containing groups were assessed: L-cysteine, 2-iminothiolane, and a cysteine polypeptide. When comparing the immobilized concentrations of thiol groups from each of the optimized processes the amount of immobilized thiol groups increased in order with the following groups: cysteine polypeptide <2-iminothiolane <L-cysteine. The effect of each optimized polymer on platelet adhesion was studied by in vitro experiments utilizing a parallel plate perfusion chamber. Platelets in the following solutions were tested: Tyrode's buffer, 7 microm nitrosated bovine serum albumin in Tyrode's buffer, 50% plasma in Tyrode's buffer, and 50% whole blood in Tyrode's buffer. All of the polymers demonstrated a significant decrease in platelet adhesion compared to controls when exposed to the BSANO, plasma and whole blood solutions. The most significant decrease was for the L-cysteine modified polymer in the plasma solution with a 65% decrease.